Rhofade, a once-daily topical cream, was initially approved by the Food and Drug Administration (FDA) in January 2017. Oxymetazoline is an alpha-1A adrenorceptor agonist that acts as a vasoconstrictor. The FDA approval of Rhofade was based on data from two identical, multicentered, randomized, double-blind, parallel-group, and vehicle-controlled trials in moderate or severe patients (n=885).
Rhofade applied once-daily demonstrated a reduction in persistent facial erythema associated with rosacea through 12 hours in both clinical trials. It also demonstrated greater efficacy vs. vehicle in reducing persistent facial erythema associated with rosacea in adults.
Rhofade is available as a 1% cream in 30g tubes.
For more information call (800) 433-8871 or visit Rhofade.com.